Literature DB >> 26100709

The times they are a-changin': carbapenems for extended-spectrum-β-lactamase-producing bacteria.

Jesús Rodríguez-Baño1.   

Abstract

Several antimicrobial agents are being investigated as alternatives to carbapenems in the treatment of infections caused by ESBL-producing Enterobacteriaceae, which may be useful in avoiding overuse of carbapenems in the context of recent global spread of carbapenem-resistant Enterobacteriaceae. The most promising candidates for invasive infections so far are β-lactam/β-lactamase inhibitor combinations and cephamycins.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26100709      PMCID： PMC4538486          DOI： 10.1128/AAC.01333-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

1.  Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).

Authors:  Daryl J Hoban; Samuel K Bouchillon; Stephen P Hawser; Robert E Badal; Vincent J Labombardi; Joseph DiPersio
Journal:  Antimicrob Agents Chemother       Date:  2010-05-10       Impact factor: 5.191

Review 2.  Are susceptibility tests enough, or should laboratories still seek ESBLs and carbapenemases directly?

Authors:  David M Livermore; Jenny M Andrews; Peter M Hawkey; Pak-Leung Ho; Yoram Keness; Yohei Doi; David Paterson; Neil Woodford
Journal:  J Antimicrob Chemother       Date:  2012-03-29       Impact factor: 5.790

Review 3.  The spread of CTX-M-type extended-spectrum beta-lactamases.

Authors:  G M Rossolini; M M D'Andrea; C Mugnaioli
Journal:  Clin Microbiol Infect       Date:  2008-01       Impact factor: 8.067

4.  Temocillin use in England: clinical and microbiological efficacies in infections caused by extended-spectrum and/or derepressed AmpC β-lactamase-producing Enterobacteriaceae.

Authors:  Indran Balakrishnan; F Mustafa Awad-El-Kariem; Adnan Aali; Prasanna Kumari; Rohinton Mulla; Benny Tan; Daniel Brudney; David Ladenheim; Anan Ghazy; Imran Khan; Nilangi Virgincar; Shabnam Iyer; Stephane Carryn; Sebastien Van de Velde
Journal:  J Antimicrob Chemother       Date:  2011-08-02       Impact factor: 5.790

5.  Impact of changes in CLSI and EUCAST breakpoints for susceptibility in bloodstream infections due to extended-spectrum β-lactamase-producing Escherichia coli.

Authors:  J Rodríguez-Baño; E Picón; M D Navarro; L López-Cerero; A Pascual
Journal:  Clin Microbiol Infect       Date:  2011-10-10       Impact factor: 8.067

6.  Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data.

Authors:  Thomas P Van Boeckel; Sumanth Gandra; Ashvin Ashok; Quentin Caudron; Bryan T Grenfell; Simon A Levin; Ramanan Laxminarayan
Journal:  Lancet Infect Dis       Date:  2014-07-09       Impact factor: 25.071

7.  β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts.

Authors:  Jesús Rodríguez-Baño; María Dolores Navarro; Pilar Retamar; Encarnación Picón; Álvaro Pascual
Journal:  Clin Infect Dis       Date:  2011-11-04       Impact factor: 9.079

Review 8.  Extended-spectrum beta-lactamases: a clinical update.

Authors:  David L Paterson; Robert A Bonomo
Journal:  Clin Microbiol Rev       Date:  2005-10       Impact factor: 26.132

Review 9.  Global spread of Carbapenemase-producing Enterobacteriaceae.

Authors:  Patrice Nordmann; Thierry Naas; Laurent Poirel
Journal:  Emerg Infect Dis       Date:  2011-10       Impact factor: 6.883

10.  Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli (FOREST): study protocol for an investigator-driven randomised controlled trial.

Authors:  Clara Rosso-Fernández; Jesús Sojo-Dorado; Angel Barriga; Lucía Lavín-Alconero; Zaira Palacios; Inmaculada López-Hernández; Vicente Merino; Manuel Camean; Alvaro Pascual; Jesús Rodríguez-Baño
Journal:  BMJ Open       Date:  2015-03-31       Impact factor: 2.692
View more
  5 in total

1.  ESBL Detection: Comparison of a Commercially Available Chromogenic Test for Third Generation Cephalosporine Resistance and Automated Susceptibility Testing in Enterobactericeae.

Authors:  Mohamed Ramadan El-Jade; Marijo Parcina; Ricarda Maria Schmithausen; Christoph Stein; Alina Meilaender; Achim Hoerauf; Ernst Molitor; Isabelle Bekeredjian-Ding
Journal:  PLoS One       Date:  2016-08-05       Impact factor: 3.240

2.  Comparative Activities of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Enterobacteriaceae Isolates Producing Extended-Spectrum β-Lactamases from U.S. Hospitals.

Authors:  Mariana Castanheira; Timothy B Doyle; Rodrigo E Mendes; Helio S Sader
Journal:  Antimicrob Agents Chemother       Date:  2019-06-24       Impact factor: 5.191

3.  Prevalence of Aminoglycoside-Modifying Enzymes in Escherichia coli and Klebsiella pneumoniae Producing Extended Spectrum β-Lactamases Collected in Two Multicenter Studies in Spain.

Authors:  Marta Fernández-Martínez; Belén Ruiz Del Castillo; Maria Jesús Lecea-Cuello; Jesús Rodríguez-Baño; Álvaro Pascual; Luis Martínez-Martínez
Journal:  Microb Drug Resist       Date:  2017-10-03       Impact factor: 3.431

4.  A novel framework to compare the effectiveness of β-lactamase inhibitors against extended-spectrum β-lactamase-producing Enterobacteriaceae.

Authors:  H Abodakpi; K T Chang; J Zhou; C Byerly; V H Tam
Journal:  Clin Microbiol Infect       Date:  2019-01-18       Impact factor: 8.067

5.  Elevated prevalence of multidrug-resistant gram-negative organisms in HIV positive men.

Authors:  Claudia Reinheimer; Oliver T Keppler; Christoph Stephan; Thomas A Wichelhaus; Imke Friedrichs; Volkhard A J Kempf
Journal:  BMC Infect Dis       Date:  2017-03-13       Impact factor: 3.090
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.